Morgan Stanley Solid Biosciences Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.51 - $7.56 $29,121 - $431,683	-57,101 Reduced 36.14%	100,904 $47,000
Q2 2022 Oct 27, 2022	BUY	$0.43 - $1.24 $15,377 - $44,343	35,761 Added 29.25%	158,005 $97,000
Q2 2022 Aug 15, 2022	BUY	$0.43 - $1.24 $15,377 - $44,343	35,761 Added 29.25%	158,005 $97,000
Q1 2022 Oct 27, 2022	SELL	$0.74 - $1.79 $26,463 - $64,012	-35,761 Reduced 22.63%	122,244 $147,000
Q1 2022 May 13, 2022	SELL	$0.74 - $1.79 $177,132 - $428,468	-239,368 Reduced 66.19%	122,244 $147,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $456,654 - $664,716	270,210 Added 295.63%	361,612 $632,000
Q3 2021 Nov 15, 2021	BUY	$2.38 - $3.77 $217,536 - $344,585	91,402 New	91,402 $217,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $30.6M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.